Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.18−0.15 (-11.28%)
Close on Nov 13, 2026Market cap $118.40MP/E –Yield –
Cellectis enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Cellectis's enterprise value was $103.37M on Nov 11, 2026, against $448.84M a year earlier. Over the last 5 years it ranged from -$51.29M to $448.84M, with a median of $36.04M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $103.37M | -75.7% |
| 2025 | Dec 31, 2025 | $425.77M | +1267.9% |
| 2024 | Dec 31, 2024 | $31.13M | -77.8% |
| 2023 | Dec 29, 2023 | $140.29M | – |
| 2022 | Dec 30, 2022 | -$22.28M | -115.1% |
| 2021 | Dec 31, 2021 | $147.38M | -84.1% |
| 2020 | Dec 31, 2020 | $926.42M | +193.3% |
| 2019 | Dec 31, 2019 | $315.87M | -12.6% |
| 2018 | Dec 31, 2018 | $361.47M | -53.5% |
| 2017 | Dec 29, 2017 | $777.32M | +204.9% |
| 2016 | Dec 30, 2016 | $254.96M | -67.1% |
| 2015 | Dec 31, 2015 | $775.80M | – |
See a number that looks wrong?